Trait Information | |
Identifier | MONDO_0005148 |
Description | A type of diabetes mellitus that is characterized by insulin resistance or desensitization and increased blood glucose levels. This is a chronic disease that can develop gradually over the life of a patient and can be linked to both environmental factors and heredity. [NCIT: P378] | Trait categories |
Digestive system disorder
Metabolic disorder
|
Synonyms |
30 synonyms
|
Mapped terms |
8 mapped terms
|
Polygenic Score ID & Name | PGS Publication ID (PGP) | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants | Ancestry distribution | Scoring File (FTP Link) |
---|---|---|---|---|---|---|
PGS000014 (GPS_T2D) |
PGP000006 | Khera AV et al. Nat Genet (2018) |
Type 2 diabetes | type 2 diabetes mellitus | 6,917,436 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000014/ScoringFiles/PGS000014.txt.gz | |
PGS000020 (dGRS1000) |
PGP000010 | Läll K et al. Genet Med (2016) |
Type 2 diabetes | type 2 diabetes mellitus | 7,502 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000020/ScoringFiles/PGS000020.txt.gz |
PGS000031 (GRSt) |
PGP000020 | Vassy JL et al. Diabetes (2014) |
Type 2 diabetes | type 2 diabetes mellitus | 62 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000031/ScoringFiles/PGS000031.txt.gz |
PGS000032 (GRSB) |
PGP000020 | Vassy JL et al. Diabetes (2014) |
Type 2 diabetes (based on SNPs involved in β-cell function) | type 2 diabetes mellitus | 20 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000032/ScoringFiles/PGS000032.txt.gz |
PGS000033 (GRSIR) |
PGP000020 | Vassy JL et al. Diabetes (2014) |
Type 2 diabetes (based on SNPs involved in insulin resistance) | type 2 diabetes mellitus | 10 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000033/ScoringFiles/PGS000033.txt.gz |
PGS000036 (gePS_T2D) |
PGP000023 | Mahajan A et al. Nat Genet (2018) |
Type 2 diabetes | type 2 diabetes mellitus | 171,249 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000036/ScoringFiles/PGS000036.txt.gz | |
PGS000125 (Qi_T2D_2017) |
PGP000062 | Qi Q et al. Diabetes (2017) |
Type 2 Diabetes | type 2 diabetes mellitus | 80 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000125/ScoringFiles/PGS000125.txt.gz |
PGS000330 (PRS_T2D) |
PGP000100 | Mars N et al. Nat Med (2020) |
Type 2 diabetes | type 2 diabetes mellitus | 6,437,380 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000330/ScoringFiles/PGS000330.txt.gz | |
PGS000712 (T2D_HbA1c_39) |
PGP000128 | Sinnott-Armstrong N et al. Nat Genet (2021) |
T2D (cases vs HbA1c filtered controls) | type 2 diabetes mellitus | 183,695 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000712/ScoringFiles/PGS000712.txt.gz |
PGS000713 (T2D) |
PGP000128 | Sinnott-Armstrong N et al. Nat Genet (2021) |
T2D | type 2 diabetes mellitus | 183,830 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000713/ScoringFiles/PGS000713.txt.gz |
PGS000729 (T2D_PGS) |
PGP000137 | Ritchie SC et al. Nat Metab (2021) |
Type 2 diabetes | type 2 diabetes mellitus | 2,017,388 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000729/ScoringFiles/PGS000729.txt.gz |
PGS000804 (GRS582_T2Dmulti) |
PGP000193 | Polfus LM et al. HGG Adv (2021) |
Type 2 diabetes | type 2 diabetes mellitus | 582 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000804/ScoringFiles/PGS000804.txt.gz |
PGS000805 (GRS582_T2Deur) |
PGP000193 | Polfus LM et al. HGG Adv (2021) |
Type 2 diabetes | type 2 diabetes mellitus | 582 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000805/ScoringFiles/PGS000805.txt.gz |
PGS000806 (GRS582_T2Dafr) |
PGP000193 | Polfus LM et al. HGG Adv (2021) |
Type 2 diabetes | type 2 diabetes mellitus | 582 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000806/ScoringFiles/PGS000806.txt.gz |
PGS000807 (GRS582_T2Dasn) |
PGP000193 | Polfus LM et al. HGG Adv (2021) |
Type 2 diabetes | type 2 diabetes mellitus | 582 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000807/ScoringFiles/PGS000807.txt.gz |
PGS000808 (GRS582_T2Dhis) |
PGP000193 | Polfus LM et al. HGG Adv (2021) |
Type 2 diabetes | type 2 diabetes mellitus | 582 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000808/ScoringFiles/PGS000808.txt.gz |
PGS000832 (T2D-GRS) |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Type 2 diabetes | type 2 diabetes mellitus | 384 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000832/ScoringFiles/PGS000832.txt.gz |
PGS000848 (T2D_Adiposity) |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Type 2 diabetes (based on SNPs associated with adiposity) | type 2 diabetes mellitus | 6 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000848/ScoringFiles/PGS000848.txt.gz |
PGS000849 (T2D_Impaired_Lipids) |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Type 2 diabetes (based on SNPs associated with impaired lipids) | type 2 diabetes mellitus | 3 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000849/ScoringFiles/PGS000849.txt.gz |
PGS000850 (T2D_Insulin_Action) |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Type 2 diabetes (based on SNPs associated with insulin action) | type 2 diabetes mellitus | 16 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000850/ScoringFiles/PGS000850.txt.gz |
PGS000851 (T2D_Insulin_Action_Secretion) |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Type 2 diabetes (based on SNPs associated with insulin action/secretion) | type 2 diabetes mellitus | 37 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000851/ScoringFiles/PGS000851.txt.gz |
PGS000852 (T2D_Insulin_Secretion_1) |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Type 2 diabetes (based on SNPs associated with insulin secretion) | type 2 diabetes mellitus | 8 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000852/ScoringFiles/PGS000852.txt.gz |
PGS000853 (T2D_Insulin_Secretion_2) |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Type 2 diabetes (based on SNPs associated with insulin secretion) | type 2 diabetes mellitus | 21 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000853/ScoringFiles/PGS000853.txt.gz |
PGS000854 (T2D_BetaCell) |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Type 2 diabetes (based on SNPs associated with beta cell function) | type 2 diabetes mellitus | 27 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000854/ScoringFiles/PGS000854.txt.gz |
PGS000855 (T2D_Lipodystrophy) |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Type 2 diabetes (based on SNPs associated with lipodystrophy) | type 2 diabetes mellitus | 18 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000855/ScoringFiles/PGS000855.txt.gz |
PGS000856 (T2D_LiverLipids) |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Type 2 diabetes (based on SNPs associated with liver lipids) | type 2 diabetes mellitus | 3 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000856/ScoringFiles/PGS000856.txt.gz |
PGS000857 (T2D_Obesity) |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Type 2 diabetes (based on SNPs associated with obesity) | type 2 diabetes mellitus | 4 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000857/ScoringFiles/PGS000857.txt.gz |
PGS000858 (T2D_Proinsulin) |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Type 2 diabetes (based on SNPs associated with proinsulin levels) | type 2 diabetes mellitus | 6 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000858/ScoringFiles/PGS000858.txt.gz |
PGS000864 (T2D-gPRS) |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Type 2 diabetes | type 2 diabetes mellitus | 389,243 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000864/ScoringFiles/PGS000864.txt.gz |
PGS000868 (T2D_221) |
PGP000214 | Aksit MA et al. J Clin Endocrinol Metab (2020) |
Type II diabetes | type 2 diabetes mellitus | 221 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000868/ScoringFiles/PGS000868.txt.gz |
PGS001294 (GBE_HC649) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Non-insulin-dependent diabetes (time-to-event) | type 2 diabetes mellitus | 3,496 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001294/ScoringFiles/PGS001294.txt.gz |
PGS001295 (GBE_HC165) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Type 2 diabetes | type 2 diabetes mellitus | 385 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001295/ScoringFiles/PGS001295.txt.gz |
PGS001357 (T2D_AnnoPred_PRS) |
PGP000252 | Ye Y et al. Circ Genom Precis Med (2021) |
Type 2 diabetes | type 2 diabetes mellitus | 2,996,761 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001357/ScoringFiles/PGS001357.txt.gz | |
PGS001781 (T2D_PRSCS) |
PGP000261 | Tamlander M et al. Commun Biol (2022) |
Type 2 diabetes | type 2 diabetes mellitus | 1,091,673 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001781/ScoringFiles/PGS001781.txt.gz |
PGS001818 (portability-PLR_250.2) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Type 2 diabetes | type 2 diabetes mellitus | 30,745 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001818/ScoringFiles/PGS001818.txt.gz |
PGS002026 (portability-ldpred2_250.2) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Type 2 diabetes | type 2 diabetes mellitus | 830,783 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002026/ScoringFiles/PGS002026.txt.gz |
PGS002243 (ldpred_t2d) |
PGP000271 | Mars N et al. Cell Genom (2022) |
Type 2 diabetes | type 2 diabetes mellitus | 6,431,973 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002243/ScoringFiles/PGS002243.txt.gz | |
PGS002277 (pPS_Insulin_secretion_1) |
PGP000305 | Siddiqui MK et al. Diabetologia (2022) |
Type 2 diabetes (based on SNPs associated with insulin secretion) | type 2 diabetes mellitus | 8 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002277/ScoringFiles/PGS002277.txt.gz |
PGS Performance Metric ID (PPM) |
Evaluated Score |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|---|
PPM000023 | PGS000014 (GPS_T2D) |
PSS000017| European Ancestry| 288,978 individuals |
PGP000006 | Khera AV et al. Nat Genet (2018) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.73 [0.72, 0.73] | Nagelkerke’s R2 (estimate of variance explained by the PGS after covariate adjustment): 0.029 | age; sex; Ancestry PC 1-4; genotyping chip | — |
PPM002477 | PGS000014 (GPS_T2D) |
PSS001117| European Ancestry| 68,229 individuals |
PGP000218 | He Y et al. Diabetes Care (2021) |Ext. |
Reported Trait: Incident type II diabetes | — | C-index: 0.709 [0.696, 0.722] | Hazard ratio (HR, top 10% vs. remaining 90%): 2.0 [1.73, 2.31] | Sex, age, principal components, assessment center | — |
PPM002478 | PGS000014 (GPS_T2D) |
PSS001117| European Ancestry| 68,229 individuals |
PGP000218 | He Y et al. Diabetes Care (2021) |Ext. |
Reported Trait: Incident type II diabetes in males | — | C-index: 0.68 [0.663, 0.697] | — | Age, principal components and assessment center | — |
PPM002479 | PGS000014 (GPS_T2D) |
PSS001117| European Ancestry| 68,229 individuals |
PGP000218 | He Y et al. Diabetes Care (2021) |Ext. |
Reported Trait: Incident type II diabetes in females | — | C-index: 0.705 [0.682, 0.728] | — | Age, principal components and assessment center | — |
PPM002480 | PGS000014 (GPS_T2D) |
PSS001117| European Ancestry| 68,229 individuals |
PGP000218 | He Y et al. Diabetes Care (2021) |Ext. |
Reported Trait: Incident type II diabetes | — | C-index: 0.776 [0.764, 0.788] | — | Sex, age, principal components, assessment center, polyexposure score | — |
PPM002481 | PGS000014 (GPS_T2D) |
PSS001117| European Ancestry| 68,229 individuals |
PGP000218 | He Y et al. Diabetes Care (2021) |Ext. |
Reported Trait: Incident type II diabetes | — | C-index: 0.844 [0.834, 0.854] | — | Sex, age, principal components, assessment center, clinical risk score | — |
PPM002482 | PGS000014 (GPS_T2D) |
PSS001117| European Ancestry| 68,229 individuals |
PGP000218 | He Y et al. Diabetes Care (2021) |Ext. |
Reported Trait: Incident type II diabetes | — | C-index: 0.855 [0.845, 0.865] | — | Sex, age, principal components, assessment center, polyexposure socre, clinical risk score | — |
PPM002483 | PGS000014 (GPS_T2D) |
PSS001117| European Ancestry| 68,229 individuals |
PGP000218 | He Y et al. Diabetes Care (2021) |Ext. |
Reported Trait: Incident type II diabetes in females | — | C-index: 0.786 [0.765, 0.807] | — | Age, principal components, assessment center, polyexposure score | — |
PPM002485 | PGS000014 (GPS_T2D) |
PSS001117| European Ancestry| 68,229 individuals |
PGP000218 | He Y et al. Diabetes Care (2021) |Ext. |
Reported Trait: Incident type II diabetes in females | — | C-index: 0.859 [0.842, 0.876] | — | Sex, age, principal components, assessment center, clinical risk score | — |
PPM002486 | PGS000014 (GPS_T2D) |
PSS001117| European Ancestry| 68,229 individuals |
PGP000218 | He Y et al. Diabetes Care (2021) |Ext. |
Reported Trait: Incident type II diabetes in males | — | C-index: 0.749 [0.734, 0.764] | — | Age, principal components, assessment center, polyexposure score | — |
PPM002487 | PGS000014 (GPS_T2D) |
PSS001117| European Ancestry| 68,229 individuals |
PGP000218 | He Y et al. Diabetes Care (2021) |Ext. |
Reported Trait: Incident type II diabetes in males | — | C-index: 0.821 [0.808, 0.834] | — | Age, principal components, assessment center, polyexposure socre, clinical risk score | — |
PPM002488 | PGS000014 (GPS_T2D) |
PSS001117| European Ancestry| 68,229 individuals |
PGP000218 | He Y et al. Diabetes Care (2021) |Ext. |
Reported Trait: Incident type II diabetes in males | — | C-index: 0.834 [0.821, 0.847] | — | Sex, age, principal components, assessment center, clinical risk score | — |
PPM002484 | PGS000014 (GPS_T2D) |
PSS001117| European Ancestry| 68,229 individuals |
PGP000218 | He Y et al. Diabetes Care (2021) |Ext. |
Reported Trait: Incident type II diabetes in females | — | C-index: 0.869 [0.853, 0.885] | — | Age, principal components, assessment center, polyexposure socre, clinical risk score | — |
PPM000040 | PGS000020 (dGRS1000) |
PSS000025| European Ancestry| 6,280 individuals |
PGP000010 | Läll K et al. Genet Med (2016) |
Reported Trait: Incident type 2 diabetes | HR: 1.48 [1.32, 1.66] | C-index: 0.79 [0.771, 0.812] | — | BMI category, smoking level, waist-to-hip ratio, waist circumference, physical activity level, history of high blood glucose, fruit and vegetable consumption, and sex. | Cox age-as-time-scale |
PPM000062 | PGS000031 (GRSt) |
PSS000044| European Ancestry| 3,471 individuals |
PGP000020 | Vassy JL et al. Diabetes (2014) |
Reported Trait: Incident type 2 diabetes cases | HR: 1.06 [1.04, 1.08] | C-index: 0.906 [0.892, 0.92] | — | age, sex, family history (parents), body mass index, systolic blood pressure, fasting glucose, log-HDL cholesterol, log-triglyceride levels | Results from the "Clinical model" |
PPM000063 | PGS000031 (GRSt) |
PSS000043| European Ancestry| 1,650 individuals |
PGP000020 | Vassy JL et al. Diabetes (2014) |
Reported Trait: Incident type 2 diabetes cases | HR: 1.06 [1.02, 1.1] | C-index: 0.853 [0.81, 0.896] | — | age, sex, family history (parents), body mass index, systolic blood pressure, fasting glucose, log-HDL cholesterol, log-triglyceride levels | Results from the "Clinical model" |
PPM000064 | PGS000031 (GRSt) |
PSS000042| African Ancestry| 820 individuals |
PGP000020 | Vassy JL et al. Diabetes (2014) |
Reported Trait: Incident type 2 diabetes cases | HR: 1.05 [1.0, 1.09] | C-index: 0.771 [0.727, 0.814] | — | age, sex, family history (parents), body mass index, systolic blood pressure, fasting glucose, log-HDL cholesterol, log-triglyceride levels | Results from the "Clinical model", SNPs were not weighted by their effect size as the betas were measure in Europeans |
PPM000065 | PGS000032 (GRSB) |
PSS000044| European Ancestry| 3,471 individuals |
PGP000020 | Vassy JL et al. Diabetes (2014) |
Reported Trait: Incident type 2 diabetes cases | HR: 1.1 [1.06, 1.14] | — | — | age, sex, family history (parents), body mass index, systolic blood pressure, fasting glucose, log-HDL cholesterol, log-triglyceride levels | Results from the "Clinical model" |
PPM000066 | PGS000032 (GRSB) |
PSS000043| European Ancestry| 1,650 individuals |
PGP000020 | Vassy JL et al. Diabetes (2014) |
Reported Trait: Incident type 2 diabetes cases | HR: 1.09 [1.02, 1.17] | — | — | age, sex, family history (parents), body mass index, systolic blood pressure, fasting glucose, log-HDL cholesterol, log-triglyceride levels | Results from the "Clinical model" |
PPM000067 | PGS000032 (GRSB) |
PSS000042| African Ancestry| 820 individuals |
PGP000020 | Vassy JL et al. Diabetes (2014) |
Reported Trait: Incident type 2 diabetes cases | HR: 1.06 [0.99, 1.15] | — | — | age, sex, family history (parents), body mass index, systolic blood pressure, fasting glucose, log-HDL cholesterol, log-triglyceride levels | Results from the "Clinical model", SNPs were not weighted by their effect size as the betas were measure in Europeans |
PPM002415 | PGS000032 (GRSB) |
PSS001092| Ancestry Not Reported| 5,740 individuals |
PGP000214 | Aksit MA et al. J Clin Endocrinol Metab (2020) |Ext. |
Reported Trait: Cystic-fibrosis related diabetes onset | HR: 1.192 | — | — | PCs(1-4), site of recruitment | — |
PPM000068 | PGS000033 (GRSIR) |
PSS000044| European Ancestry| 3,471 individuals |
PGP000020 | Vassy JL et al. Diabetes (2014) |
Reported Trait: Incident type 2 diabetes cases | HR: 0.98 [0.93, 1.04] | — | — | age, sex, family history (parents), body mass index, systolic blood pressure, fasting glucose, log-HDL cholesterol, log-triglyceride levels | Results from the "Clinical model" |
PPM000069 | PGS000033 (GRSIR) |
PSS000043| European Ancestry| 1,650 individuals |
PGP000020 | Vassy JL et al. Diabetes (2014) |
Reported Trait: Incident type 2 diabetes cases | HR: 1.01 [0.91, 1.12] | — | — | age, sex, family history (parents), body mass index, systolic blood pressure, fasting glucose, log-HDL cholesterol, log-triglyceride levels | Results from the "Clinical model" |
PPM000070 | PGS000033 (GRSIR) |
PSS000042| African Ancestry| 820 individuals |
PGP000020 | Vassy JL et al. Diabetes (2014) |
Reported Trait: Incident type 2 diabetes cases | HR: 1.06 [0.99, 1.15] | — | — | age, sex, family history (parents), body mass index, systolic blood pressure, fasting glucose, log-HDL cholesterol, log-triglyceride levels | Results from the "Clinical model", SNPs were not weighted by their effect size as the betas were measure in Europeans |
PPM000080 | PGS000036 (gePS_T2D) |
PSS000054| European Ancestry| 324,870 individuals |
PGP000024 | Udler MS et al. Endocr Rev (2019) |Ext. |
Reported Trait: Type 2 diabetes | — | AUROC: 0.66 | — | genotyping array, first 6 PCs of ancestry | — |
PPM000081 | PGS000036 (gePS_T2D) |
PSS000054| European Ancestry| 324,870 individuals |
PGP000024 | Udler MS et al. Endocr Rev (2019) |Ext. |
Reported Trait: Type 2 diabetes | — | AUROC: 0.73 | — | age, sex, genotyping array, first 6 PCs of ancestry | — |
PPM000404 | PGS000125 (Qi_T2D_2017) |
PSS000232| Hispanic or Latin American Ancestry| 7,746 individuals |
PGP000062 | Qi Q et al. Diabetes (2017) |
Reported Trait: Type 2 Diabetes | — | — | OR (Odds Ratio, per risk allele): 1.07 [1.06, 1.08] | center, age, sex, 5 PCs of ancestry | Covariance matrices corresponding to genetic relatedness (kinship), household, and census block group were included as random effects in the mixed model analysis |
PPM000897 | PGS000330 (PRS_T2D) |
PSS000441| European Ancestry| 21,030 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Incident type 2 diabetes | — | C-index: 0.845 | — | age, sex, BMI, history of stroke or CHD, parental history of diabetes, SBP, DBP, HDL, triglycerides, FINRISK cohort, genotyping array/batch, 10 ancestry PCs | 10-year risk |
PPM000892 | PGS000330 (PRS_T2D) |
PSS000441| European Ancestry| 21,030 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Incident type 2 diabetes | HR: 1.7 [1.63, 1.78] | C-index: 0.763 | — | age, sex, FINRISK cohort, genotyping array/batch, 10 ancestry PCs | 10-year risk |
PPM000887 | PGS000330 (PRS_T2D) |
PSS000448| European Ancestry| 135,300 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Type 2 diabetes (incident and prevalent cases) | HR: 1.74 [1.72, 1.77] | — | — | genotyping array/batch, 10 ancestry PCs, stratified by sex | — |
PPM001604 | PGS000712 (T2D_HbA1c_39) |
PSS000755| European Ancestry| 87,413 individuals |
PGP000128 | Sinnott-Armstrong N et al. Nat Genet (2021) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.68713 | — | Age, sex, PCs(1-10) | — |
PPM001605 | PGS000713 (T2D) |
PSS000754| European Ancestry| 87,413 individuals |
PGP000128 | Sinnott-Armstrong N et al. Nat Genet (2021) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.688 | — | Age, sex, PCs(1-10) | — |
PPM001615 | PGS000713 (T2D) |
PSS000756| European Ancestry| 135,300 individuals |
PGP000128 | Sinnott-Armstrong N et al. Nat Genet (2021) |
Reported Trait: Type 2 diabetes | HR: 1.49 [1.47, 1.51] | C-index: 0.669 | — | Age as time scale, sex, batch, PCs(1-10) | — |
PPM001667 | PGS000729 (T2D_PGS) |
PSS000869| European Ancestry| 3,087 individuals |
PGP000137 | Ritchie SC et al. Nat Metab (2021) |
Reported Trait: Incident type 2 diabetes | HR: 2.0 [1.36, 2.94] | — | — | age, sex, 10 genetic PCs | — |
PPM002117 | PGS000804 (GRS582_T2Dmulti) |
PSS001044| African Ancestry| 15,609 individuals |
PGP000193 | Polfus LM et al. HGG Adv (2021) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.568 [0.5588, 0.5772] | — | — | Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts. |
PPM002119 | PGS000804 (GRS582_T2Dmulti) |
PSS001046| European Ancestry| 423,729 individuals |
PGP000193 | Polfus LM et al. HGG Adv (2021) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.825 [0.8222, 0.8279] | Odds Ratio (OR, top 10% vs middle 20%): 2.94 [2.8, 3.08] | Age, sex, body mass index, PCs(1-10) | Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts. |
PPM002121 | PGS000804 (GRS582_T2Dmulti) |
PSS001046| European Ancestry| 423,729 individuals |
PGP000193 | Polfus LM et al. HGG Adv (2021) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.6586 [0.6547, 0.6624] | — | — | Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts. |
PPM002123 | PGS000804 (GRS582_T2Dmulti) |
PSS001047| Hispanic or Latin American Ancestry| 20,486 individuals |
PGP000193 | Polfus LM et al. HGG Adv (2021) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.7293 [0.721, 0.7376] | Odds Ratio (OR, top 10% vs middle 20%): 2.39 [2.1, 2.73] | Age, sex, body mass index, study, PCs(1-10) | Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts. |
PPM002125 | PGS000804 (GRS582_T2Dmulti) |
PSS001047| Hispanic or Latin American Ancestry| 20,486 individuals |
PGP000193 | Polfus LM et al. HGG Adv (2021) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.6249 [0.6156, 0.6342] | — | — | Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts. |
PPM002127 | PGS000804 (GRS582_T2Dmulti) |
PSS001045| Additional Asian Ancestries| 4,576 individuals |
PGP000193 | Polfus LM et al. HGG Adv (2021) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.8411 [0.8298, 0.8523] | Odds Ratio (OR, top 10% vs middle 20%): 3.08 [2.4, 3.95] | Age, sex, body mass index, study, PCs(1-10) | Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts. |
PPM002129 | PGS000804 (GRS582_T2Dmulti) |
PSS001045| Additional Asian Ancestries| 4,576 individuals |
PGP000193 | Polfus LM et al. HGG Adv (2021) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.6263 [0.6101, 0.6425] | — | — | Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts. |
PPM002131 | PGS000804 (GRS582_T2Dmulti) |
PSS001048| Additional Diverse Ancestries| 3,551 individuals |
PGP000193 | Polfus LM et al. HGG Adv (2021) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.7989 [0.7845, 0.8133] | Odds Ratio (OR, top 10% vs middle 20%): 2.02 [1.54, 2.65] | Age, sex, body mass index, PCs(1-10) | Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts. |
PPM002133 | PGS000804 (GRS582_T2Dmulti) |
PSS001048| Additional Diverse Ancestries| 3,551 individuals |
PGP000193 | Polfus LM et al. HGG Adv (2021) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.6214 [0.603, 0.6399] | — | — | Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts. |
PPM002115 | PGS000804 (GRS582_T2Dmulti) |
PSS001044| African Ancestry| 15,609 individuals |
PGP000193 | Polfus LM et al. HGG Adv (2021) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.6701 [0.6615, 0.6788] | Odds Ratio (OR, top 10% vs middle 20%): 1.57 [1.39, 1.77] | Age, sex, body mass index, study, PCs(1-10) | Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts. |
PPM002120 | PGS000805 (GRS582_T2Deur) |
PSS001046| European Ancestry| 423,729 individuals |
PGP000193 | Polfus LM et al. HGG Adv (2021) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.8253 [0.8224, 0.8281] | Odds Ratio (OR, top 10% vs middle 20%): 2.95 [2.81, 3.1] | Age, sex, body mass index, PCs(1-10) | Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts. |
PPM002122 | PGS000805 (GRS582_T2Deur) |
PSS001046| European Ancestry| 423,729 individuals |
PGP000193 | Polfus LM et al. HGG Adv (2021) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.6593 [0.6555, 0.6632] | — | — | Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts. |
PPM002134 | PGS000805 (GRS582_T2Deur) |
PSS001048| Additional Diverse Ancestries| 3,551 individuals |
PGP000193 | Polfus LM et al. HGG Adv (2021) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.6213 [0.6029, 0.6397] | — | — | Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts. Population-specific weights were not available for indiviuals of an Oceanian ancestry (Native Hawaiian). Therefore, GRS582_T2Deur was utilised to predict type 2 diabetes in individuals of an Oceanian ancestry. |
PPM002132 | PGS000805 (GRS582_T2Deur) |
PSS001048| Additional Diverse Ancestries| 3,551 individuals |
PGP000193 | Polfus LM et al. HGG Adv (2021) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.7985 [0.7842, 0.8129] | Odds Ratio (OR, top 10% vs middle 20%): 2.13 [1.63, 2.79] | Age, sex, body mass index, PCs(1-10) | Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts. Population-specific weights were not available for indiviuals of an Oceanian ancestry (Native Hawaiian). Therefore, GRS582_T2Deur was utilised to predict type 2 diabetes in individuals of an Oceanian ancestry. |
PPM002116 | PGS000806 (GRS582_T2Dafr) |
PSS001044| African Ancestry| 15,609 individuals |
PGP000193 | Polfus LM et al. HGG Adv (2021) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.6656 [0.6569, 0.6743] | Odds Ratio (OR, top 10% vs middle 20%): 1.53 [1.36, 1.73] | Age, sex, body mass index, study, PCs(1-10) | Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts. |
PPM002118 | PGS000806 (GRS582_T2Dafr) |
PSS001044| African Ancestry| 15,609 individuals |
PGP000193 | Polfus LM et al. HGG Adv (2021) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.5592 [0.5499, 0.5684] | — | — | Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts. |
PPM002128 | PGS000807 (GRS582_T2Dasn) |
PSS001045| Additional Asian Ancestries| 4,576 individuals |
PGP000193 | Polfus LM et al. HGG Adv (2021) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.8388 [0.8274, 0.8502] | Odds Ratio (OR, top 10% vs middle 20%): 2.84 [2.21, 3.65] | Age, sex, body mass index, study, PCs(1-10) | Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts. |
PPM002130 | PGS000807 (GRS582_T2Dasn) |
PSS001045| Additional Asian Ancestries| 4,576 individuals |
PGP000193 | Polfus LM et al. HGG Adv (2021) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.6161 [0.5998, 0.6324] | — | — | Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts. |
PPM002135 | PGS000807 (GRS582_T2Dasn) |
PSS001048| Additional Diverse Ancestries| 3,551 individuals |
PGP000193 | Polfus LM et al. HGG Adv (2021) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.7909 [0.7763, 0.8056] | Odds Ratio (OR, top 10% vs middle 20%): 1.62 [1.23, 2.14] | Age, sex, body mass index, PCs(1-10) | Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts. Population-specific weights were not available for indiviuals of an Oceanian ancestry (Native Hawaiian). Therefore, GRS582_T2Dasn was utilised to predict type 2 diabetes in individuals of an Oceanian ancestry. |
PPM002136 | PGS000807 (GRS582_T2Dasn) |
PSS001048| Additional Diverse Ancestries| 3,551 individuals |
PGP000193 | Polfus LM et al. HGG Adv (2021) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.5768 [0.558, 0.5956] | — | — | Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts. Population-specific weights were not available for indiviuals of an Oceanian ancestry (Native Hawaiian). Therefore, GRS582_T2Dasn was utilised to predict type 2 diabetes in individuals of an Oceanian ancestry. |
PPM002124 | PGS000808 (GRS582_T2Dhis) |
PSS001047| Hispanic or Latin American Ancestry| 20,486 individuals |
PGP000193 | Polfus LM et al. HGG Adv (2021) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.7202 [0.7118, 0.7286] | Odds Ratio (OR, top 10% vs middle 20%): 2.04 [1.79, 2.32] | Age, sex, body mass index, study, PCs(1-10) | Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts. |
PPM002126 | PGS000808 (GRS582_T2Dhis) |
PSS001047| Hispanic or Latin American Ancestry| 20,486 individuals |
PGP000193 | Polfus LM et al. HGG Adv (2021) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.6098 [0.6004, 0.6192] | — | — | Only 579 SNPs from the 582 SNP GRS, were utilised with imputation INFO scores > 0.45. 3 SNPs were not included as they were not present in the cohorts. |
PPM002240 | PGS000832 (T2D-GRS) |
PSS001088| European Ancestry| 3,869 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Insulin-Resistant Diabetes | OR: 1.24 [1.16, 1.34] | — | — | PC1-10 | — |
PPM002242 | PGS000832 (T2D-GRS) |
PSS001084| European Ancestry| 5,597 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Moderate Age-Related Diabetes | OR: 1.77 [1.67, 1.88] | — | — | PC1-10 | — |
PPM002239 | PGS000832 (T2D-GRS) |
PSS001087| European Ancestry| 3,930 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Insulin-Deficient Diabetes | OR: 1.96 [1.81, 2.12] | — | — | PC1-10 | — |
PPM002238 | PGS000832 (T2D-GRS) |
PSS001086| European Ancestry| 3,194 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Autoimmune Diabetes | OR: 1.28 [1.16, 1.42] | — | — | PC1-10 | — |
PPM002241 | PGS000832 (T2D-GRS) |
PSS001085| European Ancestry| 4,116 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Moderate Obesity-related Diabetes | OR: 1.73 [1.61, 1.86] | — | — | PC1-10 | — |
PPM002323 | PGS000848 (T2D_Adiposity) |
PSS001086| European Ancestry| 3,194 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Autoimmune Diabetes | OR: 1.11 [1.0, 1.23] | — | — | PC1-10 | — |
PPM002324 | PGS000848 (T2D_Adiposity) |
PSS001087| European Ancestry| 3,930 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Insulin-Deficient Diabetes | OR: 1.1 [1.02, 1.18] | — | — | PC1-10 | — |
PPM002325 | PGS000848 (T2D_Adiposity) |
PSS001088| European Ancestry| 3,869 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Insulin-Resistant Diabetes | OR: 1.11 [1.03, 1.19] | — | — | PC1-10 | — |
PPM002326 | PGS000848 (T2D_Adiposity) |
PSS001085| European Ancestry| 4,116 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Moderate Obesity-related Diabetes | OR: 1.2 [1.12, 1.28] | — | — | PC1-10 | — |
PPM002327 | PGS000848 (T2D_Adiposity) |
PSS001084| European Ancestry| 5,597 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Moderate Age-Related Diabetes | OR: 1.06 [1.0, 1.12] | — | — | PC1-10 | — |
PPM002329 | PGS000849 (T2D_Impaired_Lipids) |
PSS001087| European Ancestry| 3,930 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Insulin-Deficient Diabetes | OR: 1.07 [1.0, 1.15] | — | — | PC1-10 | — |
PPM002330 | PGS000849 (T2D_Impaired_Lipids) |
PSS001088| European Ancestry| 3,869 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Insulin-Resistant Diabetes | OR: 1.09 [1.01, 1.17] | — | — | PC1-10 | — |
PPM002331 | PGS000849 (T2D_Impaired_Lipids) |
PSS001085| European Ancestry| 4,116 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Moderate Obesity-related Diabetes | OR: 1.0 [0.93, 1.07] | — | — | PC1-10 | — |
PPM002332 | PGS000849 (T2D_Impaired_Lipids) |
PSS001084| European Ancestry| 5,597 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Moderate Age-Related Diabetes | OR: 1.06 [1.0, 1.12] | — | — | PC1-10 | — |
PPM002328 | PGS000849 (T2D_Impaired_Lipids) |
PSS001086| European Ancestry| 3,194 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Autoimmune Diabetes | OR: 1.08 [0.97, 1.2] | — | — | PC1-10 | — |
PPM002333 | PGS000850 (T2D_Insulin_Action) |
PSS001086| European Ancestry| 3,194 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Autoimmune Diabetes | OR: 1.08 [0.98, 1.2] | — | — | PC1-10 | — |
PPM002334 | PGS000850 (T2D_Insulin_Action) |
PSS001087| European Ancestry| 3,930 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Insulin-Deficient Diabetes | OR: 1.17 [1.09, 1.25] | — | — | PC1-10 | — |
PPM002335 | PGS000850 (T2D_Insulin_Action) |
PSS001088| European Ancestry| 3,869 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Insulin-Resistant Diabetes | OR: 1.17 [1.09, 1.26] | — | — | PC1-10 | — |
PPM002337 | PGS000850 (T2D_Insulin_Action) |
PSS001084| European Ancestry| 5,597 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Moderate Age-Related Diabetes | OR: 1.16 [1.1, 1.23] | — | — | PC1-10 | — |
PPM002336 | PGS000850 (T2D_Insulin_Action) |
PSS001085| European Ancestry| 4,116 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Moderate Obesity-related Diabetes | OR: 1.14 [1.07, 1.22] | — | — | PC1-10 | — |
PPM002338 | PGS000851 (T2D_Insulin_Action_Secretion) |
PSS001086| European Ancestry| 3,194 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Autoimmune Diabetes | OR: 1.24 [1.12, 1.37] | — | — | PC1-10 | — |
PPM002339 | PGS000851 (T2D_Insulin_Action_Secretion) |
PSS001087| European Ancestry| 3,930 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Insulin-Deficient Diabetes | OR: 1.23 [1.15, 1.32] | — | — | PC1-10 | — |
PPM002340 | PGS000851 (T2D_Insulin_Action_Secretion) |
PSS001088| European Ancestry| 3,869 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Insulin-Resistant Diabetes | OR: 1.04 [0.97, 1.11] | — | — | PC1-10 | — |
PPM002341 | PGS000851 (T2D_Insulin_Action_Secretion) |
PSS001085| European Ancestry| 4,116 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Moderate Obesity-related Diabetes | OR: 1.19 [1.12, 1.28] | — | — | PC1-10 | — |
PPM002342 | PGS000851 (T2D_Insulin_Action_Secretion) |
PSS001084| European Ancestry| 5,597 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Moderate Age-Related Diabetes | OR: 1.19 [1.13, 1.26] | — | — | PC1-10 | — |
PPM002343 | PGS000852 (T2D_Insulin_Secretion_1) |
PSS001086| European Ancestry| 3,194 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Autoimmune Diabetes | OR: 1.01 [0.91, 1.12] | — | — | PC1-10 | — |
PPM002344 | PGS000852 (T2D_Insulin_Secretion_1) |
PSS001087| European Ancestry| 3,930 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Insulin-Deficient Diabetes | OR: 1.31 [1.22, 1.41] | — | — | PC1-10 | — |
PPM002345 | PGS000852 (T2D_Insulin_Secretion_1) |
PSS001088| European Ancestry| 3,869 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Insulin-Resistant Diabetes | OR: 1.04 [0.97, 1.12] | — | — | PC1-10 | — |
PPM002347 | PGS000852 (T2D_Insulin_Secretion_1) |
PSS001084| European Ancestry| 5,597 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Moderate Age-Related Diabetes | OR: 1.29 [1.22, 1.37] | — | — | PC1-10 | — |
PPM002346 | PGS000852 (T2D_Insulin_Secretion_1) |
PSS001085| European Ancestry| 4,116 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Moderate Obesity-related Diabetes | OR: 1.26 [1.18, 1.35] | — | — | PC1-10 | — |
PPM002348 | PGS000853 (T2D_Insulin_Secretion_2) |
PSS001086| European Ancestry| 3,194 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Autoimmune Diabetes | OR: 0.99 [0.9, 1.1] | — | — | PC1-10 | — |
PPM002349 | PGS000853 (T2D_Insulin_Secretion_2) |
PSS001087| European Ancestry| 3,930 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Insulin-Deficient Diabetes | OR: 1.26 [1.18, 1.36] | — | — | PC1-10 | — |
PPM002350 | PGS000853 (T2D_Insulin_Secretion_2) |
PSS001088| European Ancestry| 3,869 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Insulin-Resistant Diabetes | OR: 1.02 [0.95, 1.09] | — | — | PC1-10 | — |
PPM002351 | PGS000853 (T2D_Insulin_Secretion_2) |
PSS001085| European Ancestry| 4,116 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Moderate Obesity-related Diabetes | OR: 1.18 [1.11, 1.27] | — | — | PC1-10 | — |
PPM002352 | PGS000853 (T2D_Insulin_Secretion_2) |
PSS001084| European Ancestry| 5,597 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Moderate Age-Related Diabetes | OR: 1.23 [1.17, 1.3] | — | — | PC1-10 | — |
PPM002353 | PGS000854 (T2D_BetaCell) |
PSS001086| European Ancestry| 3,194 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Autoimmune Diabetes | OR: 1.0 [0.91, 1.11] | — | — | PC1-10 | — |
PPM002354 | PGS000854 (T2D_BetaCell) |
PSS001087| European Ancestry| 3,930 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Insulin-Deficient Diabetes | OR: 1.32 [1.23, 1.42] | — | — | PC1-10 | — |
PPM002355 | PGS000854 (T2D_BetaCell) |
PSS001088| European Ancestry| 3,869 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Insulin-Resistant Diabetes | OR: 1.01 [0.94, 1.08] | — | — | PC1-10 | — |
PPM002357 | PGS000854 (T2D_BetaCell) |
PSS001084| European Ancestry| 5,597 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Moderate Age-Related Diabetes | OR: 1.27 [1.2, 1.34] | — | — | PC1-10 | — |
PPM002356 | PGS000854 (T2D_BetaCell) |
PSS001085| European Ancestry| 4,116 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Moderate Obesity-related Diabetes | OR: 1.21 [1.13, 1.3] | — | — | PC1-10 | — |
PPM002358 | PGS000855 (T2D_Lipodystrophy) |
PSS001086| European Ancestry| 3,194 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Autoimmune Diabetes | OR: 1.12 [1.01, 1.25] | — | — | PC1-10 | — |
PPM002359 | PGS000855 (T2D_Lipodystrophy) |
PSS001087| European Ancestry| 3,930 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Insulin-Deficient Diabetes | OR: 1.23 [1.15, 1.33] | — | — | PC1-10 | — |
PPM002360 | PGS000855 (T2D_Lipodystrophy) |
PSS001088| European Ancestry| 3,869 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Insulin-Resistant Diabetes | OR: 1.15 [1.07, 1.24] | — | — | PC1-10 | — |
PPM002361 | PGS000855 (T2D_Lipodystrophy) |
PSS001085| European Ancestry| 4,116 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Moderate Obesity-related Diabetes | OR: 1.14 [1.06, 1.22] | — | — | PC1-10 | — |
PPM002362 | PGS000855 (T2D_Lipodystrophy) |
PSS001084| European Ancestry| 5,597 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Moderate Age-Related Diabetes | OR: 1.18 [1.11, 1.24] | — | — | PC1-10 | — |
PPM002363 | PGS000856 (T2D_LiverLipids) |
PSS001086| European Ancestry| 3,194 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Autoimmune Diabetes | OR: 1.35 [1.22, 1.51] | — | — | PC1-10 | — |
PPM002364 | PGS000856 (T2D_LiverLipids) |
PSS001087| European Ancestry| 3,930 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Insulin-Deficient Diabetes | OR: 1.01 [0.94, 1.08] | — | — | PC1-10 | — |
PPM002366 | PGS000856 (T2D_LiverLipids) |
PSS001085| European Ancestry| 4,116 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Moderate Obesity-related Diabetes | OR: 1.02 [0.95, 1.09] | — | — | PC1-10 | — |
PPM002367 | PGS000856 (T2D_LiverLipids) |
PSS001084| European Ancestry| 5,597 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Moderate Age-Related Diabetes | OR: 0.95 [0.9, 1.01] | — | — | PC1-10 | — |
PPM002365 | PGS000856 (T2D_LiverLipids) |
PSS001088| European Ancestry| 3,869 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Insulin-Resistant Diabetes | OR: 0.97 [0.91, 1.05] | — | — | PC1-10 | — |
PPM002368 | PGS000857 (T2D_Obesity) |
PSS001086| European Ancestry| 3,194 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Autoimmune Diabetes | OR: 1.07 [0.97, 1.19] | — | — | PC1-10 | — |
PPM002369 | PGS000857 (T2D_Obesity) |
PSS001087| European Ancestry| 3,930 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Insulin-Deficient Diabetes | OR: 1.08 [1.01, 1.16] | — | — | PC1-10 | — |
PPM002370 | PGS000857 (T2D_Obesity) |
PSS001088| European Ancestry| 3,869 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Insulin-Resistant Diabetes | OR: 1.13 [1.05, 1.22] | — | — | PC1-10 | — |
PPM002371 | PGS000857 (T2D_Obesity) |
PSS001085| European Ancestry| 4,116 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Moderate Obesity-related Diabetes | OR: 1.19 [1.11, 1.27] | — | — | PC1-10 | — |
PPM002372 | PGS000857 (T2D_Obesity) |
PSS001084| European Ancestry| 5,597 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Moderate Age-Related Diabetes | OR: 1.04 [0.99, 1.1] | — | — | PC1-10 | — |
PPM002373 | PGS000858 (T2D_Proinsulin) |
PSS001086| European Ancestry| 3,194 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Autoimmune Diabetes | OR: 0.94 [0.85, 1.04] | — | — | PC1-10 | — |
PPM002374 | PGS000858 (T2D_Proinsulin) |
PSS001087| European Ancestry| 3,930 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Insulin-Deficient Diabetes | OR: 1.14 [1.06, 1.22] | — | — | PC1-10 | — |
PPM002376 | PGS000858 (T2D_Proinsulin) |
PSS001085| European Ancestry| 4,116 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Moderate Obesity-related Diabetes | OR: 1.06 [0.99, 1.13] | — | — | PC1-10 | — |
PPM002377 | PGS000858 (T2D_Proinsulin) |
PSS001084| European Ancestry| 5,597 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Moderate Age-Related Diabetes | OR: 1.1 [1.04, 1.16] | — | — | PC1-10 | — |
PPM002375 | PGS000858 (T2D_Proinsulin) |
PSS001088| European Ancestry| 3,869 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Insulin-Resistant Diabetes | OR: 0.93 [0.87, 1.0] | — | — | PC1-10 | — |
PPM002403 | PGS000864 (T2D-gPRS) |
PSS001086| European Ancestry| 3,194 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Autoimmune Diabetes | OR: 1.42 [1.28, 1.58] | — | — | PC1-10 | — |
PPM002404 | PGS000864 (T2D-gPRS) |
PSS001087| European Ancestry| 3,930 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Insulin-Deficient Diabetes | OR: 1.93 [1.79, 2.09] | — | — | PC1-10 | — |
PPM002406 | PGS000864 (T2D-gPRS) |
PSS001085| European Ancestry| 4,116 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Moderate Obesity-related Diabetes | OR: 2.12 [1.96, 2.29] | — | — | PC1-10 | — |
PPM002407 | PGS000864 (T2D-gPRS) |
PSS001084| European Ancestry| 5,597 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Moderate Age-Related Diabetes | OR: 1.59 [1.5, 1.69] | — | — | PC1-10 | — |
PPM002405 | PGS000864 (T2D-gPRS) |
PSS001088| European Ancestry| 3,869 individuals |
PGP000211 | Aly DM et al. Nat Genet (2021) |
Reported Trait: Severe Insulin-Resistant Diabetes | OR: 1.56 [1.45, 1.69] | — | — | PC1-10 | — |
PPM002413 | PGS000868 (T2D_221) |
PSS001092| Ancestry Not Reported| 5,740 individuals |
PGP000214 | Aksit MA et al. J Clin Endocrinol Metab (2020) |
Reported Trait: Cystic-fibrosis related diabetes | HR: 1.285 | — | — | PCs(1-4), site of recruitment | — |
PPM008968 | PGS001294 (GBE_HC649) |
PSS004575| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE non-insulin-dependent diabetes mellitus | — | AUROC: 0.70052 [0.68094, 0.7201] | R²: 0.10493 Incremental AUROC (full-covars): 0.00213 PGS R2 (no covariates): 0.00615 PGS AUROC (no covariates): 0.54526 [0.52378, 0.56673] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM008969 | PGS001294 (GBE_HC649) |
PSS004576| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE non-insulin-dependent diabetes mellitus | — | AUROC: 0.75536 [0.71488, 0.79584] | R²: 0.1242 Incremental AUROC (full-covars): 0.01544 PGS R2 (no covariates): 0.01604 PGS AUROC (no covariates): 0.5808 [0.52621, 0.63538] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM008970 | PGS001294 (GBE_HC649) |
PSS004577| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE non-insulin-dependent diabetes mellitus | — | AUROC: 0.72888 [0.71557, 0.7422] | R²: 0.10344 Incremental AUROC (full-covars): 0.03534 PGS R2 (no covariates): 0.03413 PGS AUROC (no covariates): 0.63582 [0.62119, 0.65045] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM008971 | PGS001294 (GBE_HC649) |
PSS004578| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE non-insulin-dependent diabetes mellitus | — | AUROC: 0.68707 [0.67293, 0.70121] | R²: 0.11343 Incremental AUROC (full-covars): 0.01724 PGS R2 (no covariates): 0.02384 PGS AUROC (no covariates): 0.58532 [0.56986, 0.60078] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM008972 | PGS001294 (GBE_HC649) |
PSS004579| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE non-insulin-dependent diabetes mellitus | — | AUROC: 0.71038 [0.70256, 0.71821] | R²: 0.08854 Incremental AUROC (full-covars): 0.04133 PGS R2 (no covariates): 0.03493 PGS AUROC (no covariates): 0.63323 [0.62453, 0.64194] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM008973 | PGS001295 (GBE_HC165) |
PSS004312| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.68145 [0.62426, 0.73864] | R²: 0.04466 Incremental AUROC (full-covars): 0.00427 PGS R2 (no covariates): 0.00162 PGS AUROC (no covariates): 0.5359 [0.47698, 0.59482] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM008974 | PGS001295 (GBE_HC165) |
PSS004313| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.83509 [0.71831, 0.95186] | R²: 0.20575 Incremental AUROC (full-covars): -0.00085 PGS R2 (no covariates): 0.00265 PGS AUROC (no covariates): 0.56328 [0.47919, 0.64736] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM008975 | PGS001295 (GBE_HC165) |
PSS004314| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.69318 [0.65625, 0.73011] | R²: 0.04603 Incremental AUROC (full-covars): 0.0115 PGS R2 (no covariates): 0.00675 PGS AUROC (no covariates): 0.58258 [0.54116, 0.62401] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM008976 | PGS001295 (GBE_HC165) |
PSS004315| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.65806 [0.61856, 0.69756] | R²: 0.0392 Incremental AUROC (full-covars): 0.01243 PGS R2 (no covariates): 0.00618 PGS AUROC (no covariates): 0.5613 [0.5184, 0.60421] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM008977 | PGS001295 (GBE_HC165) |
PSS004316| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.68247 [0.66155, 0.70338] | R²: 0.03772 Incremental AUROC (full-covars): 0.01405 PGS R2 (no covariates): 0.00633 PGS AUROC (no covariates): 0.57592 [0.55208, 0.59975] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM005189 | PGS001357 (T2D_AnnoPred_PRS) |
PSS003606| European Ancestry| 178,138 individuals |
PGP000252 | Ye Y et al. Circ Genom Precis Med (2021) |
Reported Trait: Type 2 diabetes | — | AUROC: 0.6446 | — | Age, sex, PCs(1-10) | — |
PPM009277 | PGS001781 (T2D_PRSCS) |
PSS007684| European Ancestry| 309,154 individuals |
PGP000261 | Tamlander M et al. Commun Biol (2022) |
Reported Trait: Type 2 diabetes (incident and prevalent) | OR: 1.59 [1.57, 1.61] | AUROC: 0.758 [0.756, 0.761] | — | year of birth, sex, ten first principal components of Finnish ancestry, batch, genotyping array | — |
PPM009281 | PGS001781 (T2D_PRSCS) |
PSS007685| European Ancestry| 279,879 individuals |
PGP000261 | Tamlander M et al. Commun Biol (2022) |
Reported Trait: Incident type 2 diabetes | OR: 1.52 [1.49, 1.55] | AUROC: 0.852 [0.849, 0.855] | — | year of birth, sex, ten first principal components of Finnish ancestry, batch, genotyping array | — |
PPM009283 | PGS001781 (T2D_PRSCS) |
PSS007691| European Ancestry| 328,115 individuals |
PGP000261 | Tamlander M et al. Commun Biol (2022) |
Reported Trait: Incident type 2 diabetes | OR: 1.51 [1.48, 1.54] | AUROC: 0.669 [0.664, 0.675] | — | year of birth, sex | — |
PPM009285 | PGS001781 (T2D_PRSCS) |
PSS007686| European Ancestry| 309,154 individuals |
PGP000261 | Tamlander M et al. Commun Biol (2022) |
Reported Trait: Prevalent type 2 diabetes | OR: 1.59 [1.57, 1.61] | AUROC: 0.81 [0.808, 0.813] | — | year of birth, sex, ten first principal components of Finnish ancestry, batch, genotyping array | — |
PPM009287 | PGS001781 (T2D_PRSCS) |
PSS007692| European Ancestry| 343,672 individuals |
PGP000261 | Tamlander M et al. Commun Biol (2022) |
Reported Trait: Prevalent type 2 diabetes | OR: 1.75 [1.72, 1.78] | AUROC: 0.725 [0.721, 0.729] | — | year of birth, sex | — |
PPM009279 | PGS001781 (T2D_PRSCS) |
PSS007690| European Ancestry| 343,672 individuals |
PGP000261 | Tamlander M et al. Commun Biol (2022) |
Reported Trait: Type 2 diabetes (incident and prevalent) | OR: 1.68 [1.65, 1.7] | AUROC: 0.708 [0.705, 0.711] | — | year of birth, sex | — |
PPM009444 | PGS001818 (portability-PLR_250.2) |
PSS009288| European Ancestry| 19,931 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Type 2 diabetes | — | — | Partial Correlation (partial-r): 0.1246 [0.1109, 0.1382] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009445 | PGS001818 (portability-PLR_250.2) |
PSS009062| European Ancestry| 4,121 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Type 2 diabetes | — | — | Partial Correlation (partial-r): 0.0862 [0.0557, 0.1165] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009447 | PGS001818 (portability-PLR_250.2) |
PSS008392| Greater Middle Eastern Ancestry| 1,197 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Type 2 diabetes | — | — | Partial Correlation (partial-r): 0.1735 [0.1176, 0.2284] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009448 | PGS001818 (portability-PLR_250.2) |
PSS008170| South Asian Ancestry| 6,312 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Type 2 diabetes | — | — | Partial Correlation (partial-r): 0.1556 [0.1314, 0.1796] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009449 | PGS001818 (portability-PLR_250.2) |
PSS007957| East Asian Ancestry| 1,808 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Type 2 diabetes | — | — | Partial Correlation (partial-r): 0.0665 [0.0202, 0.1125] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009450 | PGS001818 (portability-PLR_250.2) |
PSS007738| African Ancestry| 2,476 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Type 2 diabetes | — | — | Partial Correlation (partial-r): 0.0956 [0.0562, 0.1346] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009451 | PGS001818 (portability-PLR_250.2) |
PSS008841| African Ancestry| 3,896 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Type 2 diabetes | — | — | Partial Correlation (partial-r): 0.0522 [0.0208, 0.0836] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009446 | PGS001818 (portability-PLR_250.2) |
PSS008616| European Ancestry| 6,646 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Type 2 diabetes | — | — | Partial Correlation (partial-r): 0.108 [0.0842, 0.1317] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM011082 | PGS002026 (portability-ldpred2_250.2) |
PSS009288| European Ancestry| 19,931 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Type 2 diabetes | — | — | Partial Correlation (partial-r): 0.1304 [0.1168, 0.1441] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM011083 | PGS002026 (portability-ldpred2_250.2) |
PSS009062| European Ancestry| 4,121 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Type 2 diabetes | — | — | Partial Correlation (partial-r): 0.0862 [0.0558, 0.1165] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM011084 | PGS002026 (portability-ldpred2_250.2) |
PSS008616| European Ancestry| 6,646 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Type 2 diabetes | — | — | Partial Correlation (partial-r): 0.1134 [0.0896, 0.1371] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM011085 | PGS002026 (portability-ldpred2_250.2) |
PSS008392| Greater Middle Eastern Ancestry| 1,197 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Type 2 diabetes | — | — | Partial Correlation (partial-r): 0.1764 [0.1205, 0.2312] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM011087 | PGS002026 (portability-ldpred2_250.2) |
PSS007957| East Asian Ancestry| 1,808 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Type 2 diabetes | — | — | Partial Correlation (partial-r): 0.0786 [0.0324, 0.1246] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM011088 | PGS002026 (portability-ldpred2_250.2) |
PSS007738| African Ancestry| 2,476 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Type 2 diabetes | — | — | Partial Correlation (partial-r): 0.1001 [0.0607, 0.1391] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM011089 | PGS002026 (portability-ldpred2_250.2) |
PSS008841| African Ancestry| 3,896 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Type 2 diabetes | — | — | Partial Correlation (partial-r): 0.0806 [0.0493, 0.1118] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM011086 | PGS002026 (portability-ldpred2_250.2) |
PSS008170| South Asian Ancestry| 6,312 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Type 2 diabetes | — | — | Partial Correlation (partial-r): 0.158 [0.1338, 0.182] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM012733 | PGS002243 (ldpred_t2d) |
PSS009522| European Ancestry| 258,402 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Type 2 diabetes | OR: 1.58 [1.56, 1.6] | — | — | age, sex, 10 PCs (+/- dataset-specific technical covariates) | — |
PPM012737 | PGS002243 (ldpred_t2d) |
PSS009518| European Ancestry| 110,597 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Type 2 diabetes | OR: 1.55 [1.51, 1.59] | — | — | age, sex, 10 PCs (+/- dataset-specific technical covariates) | — |
PPM012741 | PGS002243 (ldpred_t2d) |
PSS009514| East Asian Ancestry| 178,726 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Type 2 diabetes | OR: 1.37 [1.36, 1.39] | — | — | age, sex, 10 PCs (+/- dataset-specific technical covariates) | — |
PPM012745 | PGS002243 (ldpred_t2d) |
PSS009526| European Ancestry| 69,422 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Type 2 diabetes | OR: 1.64 [1.6, 1.69] | — | — | birth year, sex, 10 PCs (+/- dataset-specific technical covariates) | — |
PPM012749 | PGS002243 (ldpred_t2d) |
PSS009534| European Ancestry| 25,696 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Type 2 diabetes | OR: 1.46 [1.41, 1.51] | — | — | age, sex, 10 PCs (+/- dataset-specific technical covariates) | — |
PPM012753 | PGS002243 (ldpred_t2d) |
PSS009530| African Ancestry| 1,535 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Type 2 diabetes | OR: 1.24 [1.09, 1.42] | — | — | age, sex, 10 PCs (+/- dataset-specific technical covariates) | — |
PPM012757 | PGS002243 (ldpred_t2d) |
PSS009542| European Ancestry| 343,676 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Type 2 diabetes | OR: 1.78 [1.75, 1.81] | — | — | age, sex, 10 PCs (+/- dataset-specific technical covariates) | — |
PPM012762 | PGS002243 (ldpred_t2d) |
PSS009538| African Ancestry| 7,618 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Type 2 diabetes | OR: 1.46 [1.32, 1.62] | — | — | age, sex, 10 PCs (+/- dataset-specific technical covariates) | — |
PPM012767 | PGS002243 (ldpred_t2d) |
PSS009546| South Asian Ancestry| 7,628 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Type 2 diabetes | OR: 1.66 [1.55, 1.79] | — | — | age, sex, 10 PCs (+/- dataset-specific technical covariates) | — |
PPM012949 | PGS002277 (pPS_Insulin_secretion_1) |
PSS009629| South Asian Ancestry| 5,806 individuals |
PGP000305 | Siddiqui MK et al. Diabetologia (2022) |
Reported Trait: Age at diagnosis (overweight BMI) | β: 32.68 (20.7) | — | R²: 0.0097 | — | — |
PPM012950 | PGS002277 (pPS_Insulin_secretion_1) |
PSS009629| South Asian Ancestry| 5,806 individuals |
PGP000305 | Siddiqui MK et al. Diabetologia (2022) |
Reported Trait: Age at diagnosis (obese BMI) | β: 18.9 (10.76) | — | R²: 0.0036 | — | — |
PPM012947 | PGS002277 (pPS_Insulin_secretion_1) |
PSS009629| South Asian Ancestry| 5,806 individuals |
PGP000305 | Siddiqui MK et al. Diabetologia (2022) |
Reported Trait: Age at diagnosis | — | — | Z: 5.2 | — | Z-score p-value < 0.0001 |
PPM012948 | PGS002277 (pPS_Insulin_secretion_1) |
PSS009629| South Asian Ancestry| 5,806 individuals |
PGP000305 | Siddiqui MK et al. Diabetologia (2022) |
Reported Trait: Age at diagnosis (normal BMI) | β: 37.31 (16.7) | — | R²: 0.012 | — | — |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS009288 | — | — | 19,931 individuals | — | European | UK (+ Ireland) | UKB | — |
PSS008392 | — | — | 1,197 individuals | — | Greater Middle Eastern (Middle Eastern, North African or Persian) | Iran (Middle East) | UKB | — |
PSS009514 | — | — | [
|
— | East Asian (Japanese) |
— | BBJ | — |
PSS009518 | — | — | [
|
— | European (Estonian) |
— | EB | — |
PSS003606 | — | — | [
|
Mean = 56.81 years | European | — | UKB | — |
PSS009522 | — | — | [
|
— | European (Finnish) |
— | FinnGen | — |
PSS000042 | T2D was defined by a fasting plasma glucose ≥7.0 mmol/L (≥126 mg/dL) or report of taking diabetes medications | — | [ ,
38.8 % Male samples |
— | African American or Afro-Caribbean | — | CARDIA | — |
PSS000043 | T2D was defined by a fasting plasma glucose ≥7.0 mmol/L (≥126 mg/dL) or report of taking diabetes medications | — | [ ,
46.5 % Male samples |
— | European | — | CARDIA | — |
PSS000044 | T2D was defined by a fasting plasma glucose ≥7.0 mmol/L (≥126 mg/dL) or report of taking diabetes medications | — | [ ,
46.6 % Male samples |
— | European | — | FOS | — |
PSS009526 | — | — | [
|
— | European | Norwegian | HUNT | — |
PSS009629 | — | — | 5,806 individuals | — | South Asian (Indian) |
— | INSPIRED | Dr. Mohan’s Diabetes Specialities Centre (INSPIRED - DMDSC) |
PSS004312 | — | — | [
|
— | African unspecified | — | UKB | — |
PSS004313 | — | — | [
|
— | East Asian | — | UKB | — |
PSS004314 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
PSS004315 | — | — | [
|
— | South Asian | — | UKB | — |
PSS004316 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
PSS009534 | — | — | [
|
— | European | — | MGBB | — |
PSS009062 | — | — | 4,121 individuals | — | European | Poland (NE Europe) | UKB | — |
PSS004575 | — | — | [
|
— | African unspecified | — | UKB | — |
PSS004576 | — | — | [
|
— | East Asian | — | UKB | — |
PSS004577 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
PSS004578 | — | — | [
|
— | South Asian | — | UKB | — |
PSS004579 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
PSS008170 | — | — | 6,312 individuals | — | South Asian | India (South Asia) | UKB | — |
PSS009542 | — | — | [
|
— | European | British | UKB | — |
PSS009538 | — | — | [
|
— | African unspecified | — | UKB | — |
PSS000054 | Prevalent T2D status was defined using self-reported medical history and medication | — | [
|
— | European | — | UKB | — |
PSS009546 | — | — | [
|
— | South Asian | — | UKB | — |
PSS001084 | Moderate Age-Related Diabetes (MARD) vs. controls | — | [
|
— | European | Swedish | ANDIS | — |
PSS001085 | Moderate Obesity-related Diabetes (MOD) vs. controls | — | [
|
— | European | Swedish | ANDIS | — |
PSS001086 | Severe Autoimmune Diabetes (SAID) vs. controls | — | [
|
— | European | Swedish | ANDIS | — |
PSS001087 | Severe Insulin-Deficient Diabetes (SIDD) vs. controls | — | [
|
— | European | Swedish | ANDIS | — |
PSS001088 | Severe Insulin-Resistant Diabetes (SIRD) vs. controls | — | [
|
— | European | Swedish | ANDIS | — |
PSS001044 | Cases are individuals with type 2 diabetes (T2D). T2D cases were defined as individuals with (1) a T2D diagnosis by a physician/medical professional and use of medication for treatment of diabetes, and/or (2)a fasting(R8h)blood glucose measurement R126 mg/dL indicated in examination records. For the BMBB cohort T2D diabetes status was defined from algorithms extracted from electronic medical record (EMR) and includes family history of T2D as an exclusion criteria. For T2D cases, BMBB defined medications using unique RxNorm codes at an ingredient level and defined laboratory tests using the logical observations identifiers names and codes (LOINC) standard (https://www.phekb.org/phenotype/type-2-diabetes-mellitus). BioMe included all patients with ICD-9-CM codes of 250.x0 or 250.x2, except for codes 250.10 and 250.12 (indicative of T2D with ketoacidosis, a condition also closely associated with T1D), patients on T2D medications and/or insulin at any time, and all patients with abnormal glucose (>200 mg/dl) or hemoglobin A1c (HbA1c; ≥6.5%) laboratory test results. For the MEC cohort, T2D cases were defined using the following criteria: (a) a self-report of diabetes on the baseline questionnaire, 2nd questionnaire or 3rd questionnaire; and (b) self-report of taking medication for T2D at the time of blood draw; and (c) no diagnosis of T1D in the absence of a T2D diagnosis from the California Office of Statewide Health Planning and Development (OSHPD) for California Residents. In addition, cases included individuals who were linked to the diabetes registries of Hawaii Medical Service Association (HMSA) or Kaiser Permanente Hawaii (KPH) health plans, or who were designated as diabetic in the Chronic Conditions Data Warehouse (CCW) of Medicare. For the WHI cohort, T2D was documented at baseline by self-report in which each woman was asked whether she had ever been told that she had “sugar diabetes” by her physician. Incident diabetes during follow-up was documented by self-report at each semi-annual contact, when participants were asked, “Since the date given on the front of this form, has a doctor prescribed any of the following pills or treatments?” Choices included “pills for diabetes” and “insulin shots for diabetes.”. For the ARIC cohort prevalent type 2 diabetes was defined at the baseline examination as fasting (≥8 h) blood glucose ≥126 mg/dL, or nonfasting glucose ≥200 mg/dL, self-report physician diagnosis of diabetes or “sugar in the blood,” or current medication use for diabetes within the last two weeks. For the CARDIA cohort, T2D was determined at last visit based on a combination of measured fasting glucose levels (≥7.0 mmol/L and ≥126 mg/dL) at examination years 0, 7, 10, 15, 20, or 25; self-report of oral hypoglycemic medications or insulin at years 0, 7, 10, 15, 20, or 25; a 2-h postload glucose ≥11.1 mmol/L (≥200 mg/dL) during a 75-g oral glucose tolerance test at years 10, 20, and 25; or an HbA1c ≥6.5% at years 20 and 25. | — | [
|
— | African American or Afro-Caribbean | — | ARIC, BioMe, CARDIA, MEC, WHI | Possible sample overlap with this dataset and the datasets used to source/develop GRS582_T2Dmulti and GRS582_T2Dafr. |
PSS001045 | Cases are individuals with type 2 diabetes (T2D). T2D cases were defined as individuals with (1) a T2D diagnosis by a physician/medical professional and use of medication for treatment of diabetes,and/or (2)a fasting(R8h)blood glucose measurement R126 mg/dL indicated in examination records. For the BMBB cohort T2D diabetes status was defined from algorithms extracted from electronic medical record (EMR) and includes family history of T2D as an exclusion criteria. For T2D cases, BMBB defined medications using unique RxNorm codes at an ingredient level and defined laboratory tests using the logical observations identifiers names and codes (LOINC) standard (https://www.phekb.org/phenotype/type-2-diabetes-mellitus). BioMe included all patients with ICD-9-CM codes of 250.x0 or 250.x2, except for codes 250.10 and 250.12 (indicative of T2D with ketoacidosis, a condition also closely associated with T1D), patients on T2D medications and/or insulin at any time, and all patients with abnormal glucose (>200 mg/dl) or hemoglobin A1c (HbA1c; ≥6.5%) laboratory test results. For the MEC cohort, T2D cases were defined using the following criteria: (a) a self-report of diabetes on the baseline questionnaire, 2nd questionnaire or 3rd questionnaire; and (b) self-report of taking medication for T2D at the time of blood draw; and (c) no diagnosis of T1D in the absence of a T2D diagnosis from the California Office of Statewide Health Planning and Development (OSHPD) for California Residents. In addition, cases included individuals who were linked to the diabetes registries of Hawaii Medical Service Association (HMSA) or Kaiser Permanente Hawaii (KPH) health plans, or who were designated as diabetic in the Chronic Conditions Data Warehouse (CCW) of Medicare. For the WHI cohort, T2D was documented at baseline by self-report in which each woman was asked whether she had ever been told that she had “sugar diabetes” by her physician. Incident diabetes during follow-up was documented by self-report at each semi-annual contact, when participants were asked, “Since the date given on the front of this form, has a doctor prescribed any of the following pills or treatments?” Choices included “pills for diabetes” and “insulin shots for diabetes.”. | — | [
|
— | Asian unspecified | — | BioMe, MEC, WHI | Possible sample overlap with this dataset and the datasets used to source/develop GRS582_T2Dmulti and GRS582_T2Dasn. |
PSS001046 | Cases are individuals with type 2 diabetes (T2D). T2D cases were defined as individuals with (1) a T2D diagnosis by a physician/medical professional and use of medication for treatment of diabetes,and/or (2)a fasting(R8h)blood glucose measurement R126 mg/dL indicated in examination records. For the UKB cohort, T2D cases were defined by an ICD-10 code of E11.X or a self-reported diagnosis in an interview with a trained nurse. | — | [
|
— | European | — | UKB | Possible significant sample overlap with this dataset and the datasets used to source/develop GRS582_T2Dmulti and GRS582_T2Deur |
PSS000017 | Type 2 diabetes ascertainment was based on self-report in an interview with a trained nurse or an ICD-10 code of E11.X in hospitalization records. | — | [
|
— | European | — | UKB | UKB Phase 2 |
PSS001047 | Cases are individuals with type 2 diabetes (T2D). T2D cases were defined as individuals with (1) a T2D diagnosis by a physician/medical professional and use of medication for treatment of diabetes,and/or (2)a fasting(R8h)blood glucose measurement R126 mg/dL indicated in examination records. For the BMBB cohort T2D diabetes status was defined from algorithms extracted from electronic medical record (EMR) and includes family history of T2D as an exclusion criteria. For T2D cases, BMBB defined medications using unique RxNorm codes at an ingredient level and defined laboratory tests using the logical observations identifiers names and codes (LOINC) standard (https://www.phekb.org/phenotype/type-2-diabetes-mellitus). BioMe included all patients with ICD-9-CM codes of 250.x0 or 250.x2, except for codes 250.10 and 250.12 (indicative of T2D with ketoacidosis, a condition also closely associated with T1D), patients on T2D medications and/or insulin at any time, and all patients with abnormal glucose (>200 mg/dl) or hemoglobin A1c (HbA1c; ≥6.5%) laboratory test results. For the MEC cohort, T2D cases were defined using the following criteria: (a) a self-report of diabetes on the baseline questionnaire, 2nd questionnaire or 3rd questionnaire; and (b) self-report of taking medication for T2D at the time of blood draw; and (c) no diagnosis of T1D in the absence of a T2D diagnosis from the California Office of Statewide Health Planning and Development (OSHPD) for California Residents. In addition, cases included individuals who were linked to the diabetes registries of Hawaii Medical Service Association (HMSA) or Kaiser Permanente Hawaii (KPH) health plans, or who were designated as diabetic in the Chronic Conditions Data Warehouse (CCW) of Medicare. For the WHI cohort, T2D was documented at baseline by self-report in which each woman was asked whether she had ever been told that she had “sugar diabetes” by her physician. Incident diabetes during follow-up was documented by self-report at each semi-annual contact, when participants were asked, “Since the date given on the front of this form, has a doctor prescribed any of the following pills or treatments?” Choices included “pills for diabetes” and “insulin shots for diabetes.”. For the SOL cohort, T2D cases were defined as those with fasting time >8 h and fasting glucose levels ≥126 mg/dL, fasting ≤8 h and fasting glucose ≥200 mg/dL, post–oral glucose tolerance test glucose ≥200 mg/dL, HbA1c ≥6.5% (48 mmol/mol), or on current treatment with antihyperglycemia medications. | — | [
|
— | Hispanic or Latin American | — | BioMe, MEC, SOL, WHI | Possible sample overlap with this dataset and the datasets used to source/develop GRS582_T2Dmulti and GRS582_T2Dhis. |
PSS001048 | Cases are individuals with type 2 diabetes (T2D). T2D cases were defined as individualswith (1) a T2D diagnosis by a physician/medical professional and use of medication for treat-mentofdiabetes,and/or (2)a fasting(R8h)blood glucose measurement R126 mg/dL indicated in examination records. For the MEC cohort, T2D cases were defined using the following criteria: (a) a self-report of diabetes on the baseline questionnaire, 2nd questionnaire or 3rd questionnaire; and (b) self-report of taking medication for T2D at the time of blood draw; and (c) no diagnosis of T1D in the absence of a T2D diagnosis from the California Office of Statewide Health Planning and Development (OSHPD) for California Residents. In addition, cases included individuals who were linked to the diabetes registries of Hawaii Medical Service Association (HMSA) or Kaiser Permanente Hawaii (KPH) health plans, or who were designated as diabetic in the Chronic Conditions Data Warehouse (CCW) of Medicare. | — | [
|
— | Oceanian (Native Hawaiian) |
— | MEC | — |
PSS008841 | — | — | 3,896 individuals | — | African unspecified | Nigeria (West Africa) | UKB | — |
PSS000754 | — | — | 87,413 individuals | — | European | — | UKB | — |
PSS000755 | — | — | 87,413 individuals | — | European | — | UKB | — |
PSS000756 | ICD-10 E11.0 - E11.9 | — | [
|
— | European (Finnish) |
— | FinnGen | — |
PSS000232 | Individuals with T2D were defined as those with fasting time >8 h and fasting glucose levels ≥126 mg/dL, fasting ≤8 h and fasting glucose ≥200 mg/dL, post–oral glucose tolerance test glucose ≥200 mg/dL, HbA1c ≥6.5% (48 mmol/mol), or on current treatment with antihyperglycemia medications. | — | [ ,
39.65 % Male samples |
— | Hispanic or Latin American (Central American, Cuban, Dominican, Mexican, Puerto Rican, South American) |
Ancestry groups were defined based on a combination of self-identified Hispanic/Latino background and genetic similarity | HCHS, SOL | — |
PSS001092 | All individuals had cystic fibrosis with either 2 severe CFTR mutations and/or clinically diagnosed exocrine pancreatic insufficiency. Cases are individuals with cystic fibrosis related diabetes (CFRD).Phenotypes were obtained from extracted medical charts and CF Foundation Patient Registry through 2011. CFRD was defined by clinician diagnosis of diabetes plus insulin treatment for at least 1 year. The onset of CFRD was defined as the date at which insulin was started, if it was subsequently continued for at least 1 year. In approximately 50% of the participants, independent laboratory data (such as oral glucose tolerance test or hemoglobin A1c) were able to independently confirm the diagnosis of CFRD. Diabetes data were censored at the last clinic visit or date of solid organ transplant. | — | [ ,
47.04 % Male samples |
Mean = 20.0 years | Not reported | — | CGS, CWRU, FrGMC, JHU, UNC | — |
PSS007957 | — | — | 1,808 individuals | — | East Asian | China (East Asia) | UKB | — |
PSS009530 | — | — | [
|
— | African American or Afro-Caribbean | — | MGBB | — |
PSS000869 | CALIBER rule-based phenotyping algorithms (https://github.com/spiros/chronological-map-phenotypes#diabetes) | Median = 6.9 years | [ ,
51.0 % Male samples |
Median = 44.0 years IQR = [30.5, 54.7] years |
European | — | INTERVAL | — |
PSS000025 | Incident cases of Type 2 Diabetes in 5.63 years follow-up | — | [ ,
55.0 % Male samples |
— | European (Estonian) |
— | EB | — |
PSS008616 | — | — | 6,646 individuals | — | European | Italy (South Europe) | UKB | — |
PSS007684 | Type 2 diabetes was defined by a strict type 2 diabetes definition, that excluded type 1 diabetes, ICD 8/9/10 codes are listed in Supplementary Data 1. National registeries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2019, whichever came first. | Median = 13.0 years IQR = [7.5, 19.7] years |
[ ,
43.8 % Male samples |
Mean (Age At Baseline) = 53.2 years Sd = 17.4 years |
European (Finnish) |
— | FinnGen | — |
PSS007685 | Type 2 diabetes was defined by a strict type 2 diabetes definition, that excluded type 1 diabetes, ICD 8/9/10 codes are listed in Supplementary Data 1. National registeries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2019, whichever came first. | — | [ ,
42.9 % Male samples |
Mean (Age At Baseline) = 51.8 years Sd = 17.4 years |
European (Finnish) |
— | FinnGen | — |
PSS007686 | Type 2 diabetes was defined by a strict type 2 diabetes definition, that excluded type 1 diabetes, ICD 8/9/10 codes are listed in Supplementary Data 1. National registeries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2019, whichever came first. | — | [ ,
43.8 % Male samples |
Mean (Age At Baseline) = 53.2 years Sd = 17.4 years |
European (Finnish) |
— | FinnGen | — |
PSS007690 | Type 2 diabetes was defined by a strict type 2 diabetes definition, that excluded type 1 diabetes, ICD 9/10 codes are listed in Supplementary Data 1. National registeries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the censoring date of hospital inpatient data (UK Biobank; English hospital inpatient records up to May 2020, Scottish up to November 2016, Welsh up to March 2016), whichever came first. | Median = 10.4 years IQR = [8.3, 11.3] years |
[ ,
46.3 % Male samples |
Mean (Age At Baseline) = 57.4 years Sd = 8.0 years |
European (British) |
UK Biobank participants with non-British ancestry were excluded based on genetically inferred ancestry. | UKB | — |
PSS007691 | Type 2 diabetes was defined by a strict type 2 diabetes definition, that excluded type 1 diabetes, ICD 9/10 codes are listed in Supplementary Data 1. National registeries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the censoring date of hospital inpatient data (UK Biobank; English hospital inpatient records up to May 2020, Scottish up to November 2016, Welsh up to March 2016), whichever came first. | — | [ ,
45.5 % Male samples |
Mean (Age At Baseline) = 57.2 years Sd = 8.0 years |
European (British) |
UK Biobank participants with non-British ancestry were excluded based on genetically inferred ancestry. | UKB | — |
PSS001117 | T2D cases were defined as having an ICD-10 code of E11.X or having self-reported T2D in the in- terview. Only cases in which the individuals did not have T2D during the first assessment visit period (2006–2010) but were subsequently fol- lowed up for incident T2D events were considered. | Median = 3.58 years | [ ,
47.81 % Male samples |
— | European | — | UKB | — |
PSS007692 | Type 2 diabetes was defined by a strict type 2 diabetes definition, that excluded type 1 diabetes, ICD 9/10 codes are listed in Supplementary Data 1. National registeries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the censoring date of hospital inpatient data (UK Biobank; English hospital inpatient records up to May 2020, Scottish up to November 2016, Welsh up to March 2016), whichever came first. | — | [ ,
46.3 % Male samples |
Mean (Age At Baseline) = 57.4 years Sd = 8.0 years |
European (British) |
UK Biobank participants with non-British ancestry were excluded based on genetically inferred ancestry. | UKB | — |
PSS000441 | National registries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2018, whichever came first. Disease endpoints are defined in Table S9. | — | [ ,
47.3 % Male samples |
Mean (Age At Baseline) = 48.0 years | European (Finnish) |
— | FINRISK | FINRISK surveys from 1992, 1997, 2002 and 2007 |
PSS007738 | — | — | 2,476 individuals | — | African American or Afro-Caribbean | Carribean | UKB | — |
PSS000448 | National registries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2018, whichever came first. Disease endpoints are defined in Table S9. | — | [ ,
43.7 % Male samples |
Mean (Age At Baseline) = 59.2 years Sd = 16.6 years |
European (Finnish) |
— | FinnGen | — |